47 Rue Adrienne Bolland
Ncardia provides a broad menu of Drug Safety and Toxicity services including custom assay development
Delivers an acute cardiac safety profile of your compounds following the current protocols of the CiPA initiative for microelectrode arrays (MEA) analysis.
Provides an acute and long-term cardiac safety profile based on label-free impedance analysis of your compounds using hiPSC-derived cardiomyocytes.
Provides true force measurement to study the effect of drug candidates on the contractility and force-frequency relationships of hiPSC-derived cardiomyocyte.
Delivers a structural cardiotoxicity profile of your compounds based on the detection of cardiac specific biomarkers like Troponin I release by hiPSC-derived cardiomyocytes.
Assessment of drug-induced vascular leakage using high-content, real-time and label-free impedance-based technology that monitors changes in electrical impedance across the endothelial cell monolayer.
High-throughput screening of compound effects on cardiomyocyte electrophysiology by analyzing the intracellular calcium transients.
An analysis by impedance (contractility), electrophysiology and biomarker release (structural).